Significance of quantitative interferon-gamma levels in non-small-cell lung cancer patients' response to immune checkpoint inhibitors

T Kanai, H Suzuki, H Yoshida, A Matsushita… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: We aimed to study the association between the quantitative interferon-
gamma (IFN-γ) levels and clinical outcomes in non-small-cell lung cancer (NSCLC) patients …

The levels of interferon-gamma release as a biomarker for non-small-cell lung cancer patients receiving immune checkpoint inhibitors

T Hirashima, T Kanai, H Suzuki, H Yoshida… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: The present study aimed to prospectively examine the usefulness of
interferon-gamma (IFN-γ) release (IGR) as a biomarker in non-small-cell lung cancer …

Significance of pre-treatment interferon-gamma release in patients with non-small-cell lung cancer receiving immune checkpoint inhibitors

T Hirashima, T Kanai, H Suzuki, H Yoshida… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: We retrospectively investigated the significance of pre-treatment interferon-
gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint …

Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell …

JU Lim, HK Yoon - Cytokine, 2021 - Elsevier
For a definite indication for immunotherapy, finding appropriate biomarkers that are
predictive of treatment responses is necessary. Inflammatory cytokines which play critical …

Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor

S Kubo, N Kobayashi, K Somekawa, M Hirata… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: Immune checkpoint inhibitors (ICIs) have an important role in lung cancer
therapy. Although the programmed cell death protein-1 (PD-L1) tumor proportion score …

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

N Karachaliou, M Gonzalez-Cao… - … in medical oncology, 2018 - journals.sagepub.com
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …

Predictive factors correlated with the development of immune-related adverse events in patients with non-small cell lung cancer treated with immune checkpoint …

K Sonehara, K Tateishi, T Araki… - Cancer Management …, 2022 - Taylor & Francis
Purpose Similar to the neutrophil-to-lymphocyte ratio and lung immune prognostic index
(LIPI), immune-related adverse events (irAEs) were favorable prognostic factors in several …

[HTML][HTML] Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

C Liu, L Yang, H Xu, S Zheng, Z Wang, S Wang… - BMC medicine, 2022 - Springer
Background Cytokines have been reported to alter the response to immune checkpoint
inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations …

Association between the severity of immune-related adverse events and the prognosis in patients with non-small cell lung cancer receiving treatment with immune …

M Inomata, M Matsumoto, K Hayashi, Z Seto… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Among patients with non-small cell lung cancer (NSCLC) treated with
immune checkpoint inhibitors (ICI), survival is reported to be longer in those experiencing …

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer …

M Torasawa, T Yoshida, Y Takeyasu… - Cancer …, 2023 - Wiley Online Library
Background It is still unclear whether patients with advanced non‐small cell lung cancer
(NSCLC), with disease progression after initial immune checkpoint inhibitor (ICI) therapy …